Dasabuvir: A new direct antiviral agent for the treatment of hepatitis C

Juan Pablo Trivella, Julio Gutierrez, Paul Martin

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Introduction: Treatment of hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) has revolutionized the care of infected patients. Among these novel compounds are non-nucleoside analogs, which bind viral RNA-dependent RNA polymerase resulting in a conformational change inhibiting RNA synthesis.Areas covered: Efficacy and tolerability of treatment regimens containing the non-nucleoside analog polymerase inhibitor dasabuvir (ABT-333).Expert opinion: Dasabuvir-containing regimens achieve high rates of sustained virologic response in HCV genotype 1a and 1b-infected patients when combined with other DAAs, namely paritaprevir (ABT-450), ritonavir and ombitasvir (ABT-267). In the populations studied, dasabuvir seems to be well tolerated and safe. The major limitations of this novel drug are its genotype-restricted activity, the necessity to include ribavirin for HCV genotype 1a and the emergence of resistance if not combined with other DDAs.

Original languageEnglish (US)
Pages (from-to)617-624
Number of pages8
JournalExpert Opinion on Pharmacotherapy
Issue number4
StatePublished - Mar 1 2015


  • ABT-333
  • Antiviral agents
  • Dasabuvir
  • Hepatitis C
  • Polymerase inhibitor
  • Sustained virological response

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology


Dive into the research topics of 'Dasabuvir: A new direct antiviral agent for the treatment of hepatitis C'. Together they form a unique fingerprint.

Cite this